Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results
Date:5/7/2013

/span>, the Company's Chief Executive Officer, said, "Following the announcement of top-line data, we are now focusing our efforts and resources toward the pending NDA and MAA submissions.  We are also progressing with the U.S. Phase 2 CKD study, for which we expect to report top-line data in the third quarter of 2013."

The Company will host an investor conference call tomorrow, Wednesday, May 8, 2013, at 8:30am EDT, to discuss the Company's first quarter financial results and provide a business outlook for the remainder of 2013.In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and the New Drug Application filing with the FDA and the Marketing Authorization Application filing with the EMA are pending submission.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stages 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
4. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
5. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
6. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
8. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Balloon Market Investment Report, 2014-2016" report to their ... medical device in percutaneous coronary intervention (PCI), serves not ... as a device for pre-/post-stent dilatations. Therefore, the development ... of PCI. As national economy develops and ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... companies. Competition for innovation, increasing clinical development costs, ... with the fast-changing environment are important factors driving ... and clinical trial costs continue to rise due ... Studies conducted by industry think tanks suggest ...
(Date:9/18/2014)... 2014  KIYATEC announced today that it has ... Research (SBIR) Phase II Contract from the National ... and centers that comprise the National Institutes of ... year award, KIYATEC will expand its 3D breast ... forefront of cancer therapy strategies: 1) cancer,s interaction ...
Breaking Medicine Technology:China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3
... (NASDAQ: OPTR ) today announced the presentation ... (DDW) conference highlighting additional analyses of data from Phase ... the treatment of Clostridium difficile infection (CDI). ... first analysis aimed to identify risk factors associated with ...
... MINNEAPOLIS, May 9, 2011 BioDrain Medical, Inc. (OTC ... FDA-cleared Streamway™ System for automated surgical fluid disposal, announced ... ("EKN"), a New York-based registered broker/dealer, as its exclusive ... terms of the agreement, EKN will assist the Company ...
Cached Medicine Technology:Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 2Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 3Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 4BioDrain Medical, Inc. Retains EKN Financial Services as Its Exclusive Financial Advisor and Placement Agent 2BioDrain Medical, Inc. Retains EKN Financial Services as Its Exclusive Financial Advisor and Placement Agent 3
(Date:9/18/2014)... true: exercise is good for you. But new research ... have an added benefit for cancer patients undergoing chemotherapy. ... melanoma, found that combining exercise with chemotherapy shrunk tumors ... associate professor in the School of Nursing and director ... was the senior author on the study, which appears ...
(Date:9/18/2014)... The American College of Chest Physicians (CHEST) together ... at the annual congress of CTS that CHEST ... Clinicians specializing in pulmonary, critical care, and sleep ... participate in the event, slated for spring 2016. ... rich educational experiences including hands-on simulation training, keynote ...
(Date:9/18/2014)... (PRWEB) September 19, 2014 ... the Neighborhood Mission (Misión Barrio Adentro), which ... the healthcare system (see Section 6.1.3.). In ... in an Autonomous Service of Pharmaceutical Elaborations ... plant, which provides medicines at a cheaper ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading ... and co-founder John Cassimatis was named as one ... 2014, recognizing the region’s top healthcare and life ... of the year. , The Innovation Awards celebrate ... continue to shape the medical industry in Greater ...
(Date:9/18/2014)... Salt Lake City, UT (PRWEB) September 18, 2014 ... across North America will be recognizing their shared fundraising ... on Thursday, Sept. 25. , The first-ever Dance ... of more than $20 million projected to be raised ... at their community’s CMN Hospital. Donations generated through Dance ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2
... services company standardizes on AVG Network Edition , ... ... Pyramid Healthcare, founded in 1999, provides behavioral healthcare services for ... and behavioral problems. The company has 23 locations across Pennsylvania, ...
... (CTI) (Nasdaq and MTA: CTIC) announced today that they ... with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) ... the initial $7.5 million payment in connection with the ... up to an additional $15 million in product sales ...
... Immucor, Inc.,(Nasdaq: BLUD ), a global leader ... reported financial results,for the fiscal second quarter ended November 30, ... -- Revenue for the fiscal second quarter ... the same period last year. , ...
... of America,Inc. announced the formation of ROSA of ... ROSA of South Alabama is a joint ... P.C., Monroeville Radiation -,Oncology, P.C., and South Alabama ... of America, Inc. ROSA of South,Alabama will ...
... The following is a statement by Lois Aronstein, ... State address put forth recommendations on a number of ... financial security of New Yorkers of all ages.AARP commends ... Plus Program to 200 percent of the federal poverty ...
... also bolsters tie between vitamin D and the brain ... have identified nine genes that might make people more ... confirmed earlier reports that a variation in the vitamin ... risk for Alzheimer,s. Low levels of vitamin D ...
Cached Medicine News:Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 2Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 3Health News:Walling Data and AVG Restore Pyramid Healthcare's Efficiency 4Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 2Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 3Health News:Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals 4Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 2Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 3Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 4Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 5Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 6Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 7Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 8Health News:Immucor Announces Fiscal Second Quarter Results; Raises Fiscal 2009 EPS Guidance 9Health News:Ambulatory Services of America, Inc. Announces Joint Venture with Gulf Coast Cancer Centers 2Health News:9 Genes Are Linked to Alzheimer's 2
... Ad-Techs Foramen Ovale Electrodes provide you ... These electrodes offer the same proven design ... that they are placed using an introducing ... a smaller electrode body diameter, 3 to ...
... The Small Joint Ball Electrode ... in small joint applications. With its ... tip, controlled capsuloligamentous or tendinous tissue ... When used in conjunction with the ...
... is designed to replace the carpal scaphoid bone. ... pole which fits under a shelf formed in ... suture hole on the proximal hole for suture ... the early postoperative period until a firm capsuloligamentous ...
... two-piece Titanium (Ti-6Al-4V) screw offered in two ... of lengths. The two pieces are loaded ... A single instrument set contains all items ... Standard and Mini Kompressor Compression Screws. , ...
Medicine Products: